<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To determine the incidence of secondary <z:hpo ids='HP_0000501'>glaucoma</z:hpo> in <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A total of 230 eyes of 129 patients with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet disease</z:e>, were examined in <z:hpo ids='HP_0000554'>uveitis</z:hpo> and <z:hpo ids='HP_0000501'>glaucoma</z:hpo> clinics of Ankara Social Security Eye Hospital between January 1997 and September 2002 </plain></SENT>
<SENT sid="2" pm="."><plain>The data from <z:hpo ids='HP_0000001'>all</z:hpo> patients were investigated both retrospectively and prospectively </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The mean age of 129 patients was 34.2 +/- 7.4 years (range, 18 to 55 years) </plain></SENT>
<SENT sid="4" pm="."><plain>In 22 patients (17%), the disease was diagnosed on the basis of the ocular findings, while in the remaining 107 patients (83%), the period between the diagnosis of <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet disease</z:e> and the <z:hpo ids='HP_0003674'>onset</z:hpo> of the ocular symptoms was 23.3 +/- 17 months (range, 1 month to 5.3 years); 122 eyes (53%) had the episodes of <z:hpo ids='HP_0011009'>acute</z:hpo> recurrent <z:hpo ids='HP_0001094'>iridocyclitis</z:hpo>, while 108 eyes (47%) developed <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0012123'>posterior uveitis</z:hpo>, including <z:hpo ids='HP_0011531'>vitreitis</z:hpo>, <z:e sem="disease" ids="C0035333" disease_type="Disease or Syndrome" abbrv="">retinitis</z:e>, <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, or optic nerve involvement </plain></SENT>
<SENT sid="5" pm="."><plain>Secondary <z:hpo ids='HP_0000501'>glaucoma</z:hpo> was diagnosed in 25 eyes (10.9%); 11 eyes (44%) with steroid or <z:mp ids='MP_0001845'>inflammation</z:mp> induced open angle <z:hpo ids='HP_0000501'>glaucoma</z:hpo>, 6 eyes (24%) with partial angle-closure <z:hpo ids='HP_0000501'>glaucoma</z:hpo> and peripheral <z:mp ids='MP_0011481'>anterior synechiae</z:mp>, 5 eyes (20%) with angle closure <z:hpo ids='HP_0000501'>glaucoma</z:hpo>, peripheral <z:mp ids='MP_0011481'>anterior synechiae</z:mp>, and pupil block and 3 eyes (12%) with neovascular <z:hpo ids='HP_0000501'>glaucoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The treatments included YAG-laser iridotomy in 5 eyes, diode-laser cyclodestruction in 3 eyes, primary trabeculectomies with <z:chebi fb="0" ids="25357">mitomycin</z:chebi>-c in 4 eyes, secondary trabeculectomies with <z:chebi fb="0" ids="25357">mitomycin</z:chebi>-c in 2 eyes, Ahmed valve implantations in 2 eyes, and cyclocryotherapy in 3 eyes </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: We suggest that secondary <z:hpo ids='HP_0000501'>glaucoma</z:hpo> is a common and serious complication of <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet disease</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>It develops as a result of multiple factors, generally triggered by recurrent intraocular <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>Early recognition and treatment of these factors have vital importance to avoid the visual morbidity </plain></SENT>
</text></document>